Using AI and Peer Coaching to Address Racial Disparities Among People Who Use Opioids
NCT06569667
Recruiting
Black and Latinx people who use opioids are disproportionately impacted by opioid overdose deaths. The proposed study assesses the efficacy of an open source, multimodal artificial intelligence-driven texting tool combined with peer recovery coach-supported text contact that delivers social services, stigma reduction, health habitus, and patient navigation content addressing social determinants of health to enhance receipt of buprenorphine in primary care among emergency department-enrolled Blac... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/06/2025
Locations: NYC Health + Hospitals, Bronx, New York
Conditions: Opioid Use Disorder
Register for Updates
Ostomy Simulation for Patient Education Prior to Urologic Bowel Diversion Surgeries
NCT06583577
Recruiting
The purpose of this study is to evaluate the feasibility of using a realistic and anatomically accurate 3D printed simulation model for urologic bowel diversion patient education. Using a randomized two group design, we aim to determine whether the use of this model enhances patient knowledge, self-care skills, and confidence in ostomy care. We will also evaluate changes in quality of life (QOL) and patient satisfaction comparing patients exposed to the 3D model to those receiving standard of ca... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Ostomy, Ileal Conduit
Register for Updates
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
NCT05486468
Recruiting
The Use of Two YUTIQ versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment (TYNI Trial)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Texas Retina Associates, Plano, Texas
Conditions: Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate
Register for Updates
Volrustomig Priming Regimens Exploratory Phase II Platform Study
NCT06448754
Recruiting
Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
08/06/2025
Locations: Research Site, Los Angeles, California +75 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
Evaluation of Outcomes of the Triathlon Hinge Knee (THK) System
NCT06379321
Recruiting
This study is a prospectively and retrospectively enrolled, post-market, open-label, non-randomized, single institution evaluation of clinical outcomes of primary or revision knee surgery patients who meet the eligibility criteria and received devices from the Triathlon Hinge Knee System according to its indications for use (IFU). Clinical evaluation for all cases will include data collection of patient demographics, surgical details, early postoperative status, functional and clinical outcomes... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/06/2025
Locations: Cleveland Clinic Florida, Weston, Florida +1 locations
Conditions: Knee Arthropathy, Recurrence, Knee Infection
Register for Updates
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
NCT06531499
Recruiting
The purpose of the study is to assess and evaluate dosimetry, safety, and tolerability following administration of up to 12 cycles of (177Lu) vipivotide tetraxetan (also referred to as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereafter identified as AAA617) in taxane-naïve adult participants with PSMA-positive mCRPC who progressed on a prior ARPI treatment with normal renal function or mild renal impairment (eGFR ≥ 60ml/min).
Gender:
MALE
Ages:
Between 18 years and 100 years
Trial Updated:
08/06/2025
Locations: Stanford University, Palo Alto, California +11 locations
Conditions: Metastatic Castration-Resistant Prostate Cancer
Register for Updates
Health Equity and Rural Education (HERE!) Clinical Trial
NCT06460116
Recruiting
The goal of this community-engaged research is two-fold. The first goal is to gather stakeholder feedback to inform a school-based community health worker intervention with youth with poor school attendance and an enhanced usual care condition. The second goal is to evaluate the feasibility of implementing the school-based community health worker intervention and enhanced usual care approach within rural schools. The main question it aims to answer is whether it is feasibile to recruit children... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/06/2025
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Behavioral Symptoms, Community Health Workers, Social Determinants of Health, Educational Problems
Register for Updates
Listening Effort in Cochlear Implant Users
NCT06516575
Recruiting
People with hearing loss experience extra effort when listening, which can lead to severe psychological barriers to communication and social participation. Listening effort can lead to fatigue, mental strain, burnout, medical sick leave, and the need for increased time to recover from regular daily activities. This proposal aims to understand effort changes on a moment-to-moment basis during listening, how long the effort lasts, and how the planning and execution of effort is impacted by the exp... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/06/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Auditory Perception; Abnormal, Hearing Loss, Sensorineural, Hearing Loss
Register for Updates
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247
Recruiting
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AML).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/06/2025
Locations: City of Hope Phoenix, Goodyear, Arizona +267 locations
Conditions: Leukemia
Register for Updates
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
NCT06236724
Recruiting
To learn if asciminib can help to control CML. The safety and effects of this drug will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Chronic Myeloid Leukemia
Register for Updates
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
NCT06484062
Recruiting
This phase I trial tests the safety, side effects, and best dose of SM08502 (cirtuvivint) alone and in combination with ASTX727 in treating patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Cirtuvivint may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. ASTX727 is a combination of two drugs, decitabine and cedazuridine. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow p... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: University of Chicago Comprehensive Cancer Center, Chicago, Illinois +1 locations
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
Register for Updates
Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs
NCT06411223
Recruiting
This study addresses real-world use of long-acting injectable cabotegravir/rilpivirine (CAB/RPV LA) by evaluating implementation and clinical outcomes of a pharmacist-led collaborative drug therapy management model (CDTM+) that will be expanded for telehealth outreach to women with health-related social needs (HRSN).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Yale Clinical and Community Research, New Haven, Connecticut
Conditions: Hiv
Register for Updates